James P. Zallie
Known title: President and CEOCIK: 0001502632
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target. Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.
Transaction History
| SLVM | ▲ Buy | Grant | 3,876 | $150K | 5/15/2026 | View on chart |
| INGR | ▲ Buy | Grant | 28,829 | $3.4M | 2/25/2026 | View on chart |
| INGR | ▼ Sell | Open Market | 9,958 | $1.2M | 2/18/2026 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 7,198 | $852K | 2/17/2026 | View on chart |
| INGR | ▼ Sell | Open Market | 33,597 | $4.0M | 2/11/2026 | View on chart |
| INGR | ▲ Buy | Grant | 58,096 | $0 | 2/9/2026 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 24,499 | $2.9M | 2/9/2026 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 634 | $76K | 10/10/2025 | View on chart |
| INGR | ▲ Buy | Option Exercise | 96,316 | $8.8M | 8/12/2025 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 81,634 | $10.3M | 8/12/2025 | View on chart |
| INGR | ▲ Buy | Option Exercise | 128,522 | $11.4M | 8/12/2025 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 106,917 | $13.5M | 8/12/2025 | View on chart |
| INGR | ▼ Sell | Open Market | 36,287 | $4.6M | 8/12/2025 | View on chart |
| SLVM | ▲ Buy | Grant | 2,655 | $150K | 5/15/2025 | View on chart |
| INGR | ▲ Buy | Grant | 15,424 | $2.0M | 2/26/2025 | View on chart |
| INGR | ▼ Sell | Open Market | 10,815 | $1.4M | 2/19/2025 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 7,816 | $991K | 2/16/2025 | View on chart |
| INGR | ▼ Sell | Open Market | 39,329 | $5.0M | 2/14/2025 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 29,187 | $3.8M | 2/11/2025 | View on chart |
| INGR | ▲ Buy | Grant | 68,516 | $0 | 2/11/2025 | View on chart |
| INGR | ▼ Sell | Open Market | 371 | $50K | 10/10/2024 | View on chart |
| INGR | ▲ Buy | Option Exercise | 22,550 | $2.3M | 8/30/2024 | View on chart |
| INGR | ▼ Sell | Open Market | 22,550 | $3.0M | 8/30/2024 | View on chart |
| INGR | ▲ Buy | Option Exercise | 3,981 | $398K | 8/29/2024 | View on chart |
| INGR | ▼ Sell | Open Market | 3,981 | $534K | 8/29/2024 | View on chart |
| INGR | ▲ Buy | Option Exercise | 1,300 | $130K | 8/28/2024 | View on chart |
| INGR | ▼ Sell | Open Market | 1,300 | $174K | 8/28/2024 | View on chart |
| INGR | ▲ Buy | Option Exercise | 1,000 | $100K | 8/26/2024 | View on chart |
| INGR | ▼ Sell | Open Market | 1,000 | $134K | 8/26/2024 | View on chart |
| INGR | ▼ Sell | Open Market | 27,500 | $3.2M | 6/3/2024 | View on chart |
| INGR | ▲ Buy | Option Exercise | 27,500 | $2.3M | 6/3/2024 | View on chart |
| SLVM | ▲ Buy | Grant | 1,779 | $125K | 5/16/2024 | View on chart |
| INGR | ▼ Sell | Open Market | 54,581 | $6.4M | 3/4/2024 | View on chart |
| INGR | ▲ Buy | Grant | 15,546 | $1.7M | 2/13/2024 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 33,018 | $3.6M | 2/12/2024 | View on chart |
| INGR | ▲ Buy | Grant | 74,532 | $0 | 2/12/2024 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 7,248 | $784K | 2/9/2024 | View on chart |
| INGR | ▼ Sell | Open Market | 0 | $42 | 2/9/2024 | View on chart |
| INGR | ▼ Sell | Other | 26,140 | $0 | 7/7/2023 | View on chart |
| INGR | ▼ Sell | Other | 26,140 | $0 | 7/7/2023 | View on chart |
| SLVM | ▲ Buy | Grant | 2,963 | $0 | 5/16/2023 | View on chart |
| INGR | ▲ Buy | Grant | 15,838 | $1.6M | 2/15/2023 | View on chart |
| INGR | ▲ Buy | Grant | 25,677 | $0 | 2/14/2023 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 11,375 | $1.1M | 2/14/2023 | View on chart |
| INGR | ▼ Sell | Open Market | 1 | $86 | 2/4/2023 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 6,408 | $655K | 2/4/2023 | View on chart |
| INGR | ▼ Sell | Other | 30,437 | $0 | 12/28/2022 | View on chart |
| INGR | ▼ Sell | Other | 30,437 | $0 | 12/28/2022 | View on chart |
| INGR | ▼ Sell | Other | 16,953 | $0 | 12/23/2022 | View on chart |
| INGR | ▼ Sell | Other | 16,953 | $0 | 12/23/2022 | View on chart |
| SLVM | ▲ Buy | Grant | 2,623 | $0 | 5/16/2022 | View on chart |
| INGR | ▲ Buy | Grant | 17,129 | $1.5M | 2/16/2022 | View on chart |
| INGR | ▼ Sell | Tax Withholding | 5,247 | $453K | 2/8/2022 | View on chart |
| INGR | ▼ Sell | Open Market | 0 | $19 | 2/8/2022 | View on chart |
| SLVM | ▲ Buy | Grant | 2,809 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sylvamo Price Targets Lowered by BofA and Truist
Bank of America and Truist Securities recently lowered their price targets for Sylvamo, citing updated outlooks. While BofA maintains a Neutral rating with a $42 target, Truist keeps a Buy rating but reduced its target to $40. These adjustments place the new targets below the current average analyst estimate of $50.40, reflecting a more cautious view on the company's near-term valuation.
Sylvamo Price Targets Lowered by BofA and Truist. Bank of America and Truist Securities recently lowered their price targets for Sylvamo, citing updated outlooks. While BofA maintains a Neutral rating with a $42 target, Truist keeps a Buy rating but reduced its target to $40. These adjustments place the new targets below the current average analyst estimate of $50.40, reflecting a more cautious view on the company's near-term valuation.